Sun Pharma gets CDSCO panel nod to study COPD drug combination
New Delhi: Pharmaceutical major, Sun Pharma has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the active Post-marketing Surveillance (PMS) Study of the fixed-dose combination drug Fluticasone Furoate 200mcg plus Vilanterol 25mcg powder for inhalation.
Furthermore, the expert panel suggested, "The details of the last visit including the test parameters should be mentioned at 06 months and telephonic follow-up should be done in the 4th and 5th months to assess the symptom analysis so as to rule out any worsening or exacerbation."
This came after the drug major Sun Pharma presented the active post-marketing surveillance (PMS) study protocol before the committee as per the condition mentioned in Form CT-23 dated 31.10.2022.
The fixed-dose combination drug Fluticasone Furoate 200mcg plus Vilanterol 25mcg powder for inhalation is used in the treatment of Chronic obstructive pulmonary disease (COPD) and Asthma.
Fluticasone furoate works by blocking the production of certain chemicals in the body which causes inflammation (redness and swelling) and allergies. Vilanterol works by relaxing air passages in the lungs, making breathing easier.
At the recent SEC meeting for Pulmonary held on the 21st of March 2023, the expert panel reviewed the active PMS study protocol of the FDC drug Fluticasone Furoate 200mcg plus Vilanterol 25mcg powder for inhalation.
After detailed deliberation, the committee recommended for conducting the active PMS study with the following conditions:
1. The follow-up of the study should be up to 06 months.
2. The details of the last visit including the test parameters should be mentioned at 06 months accordingly.
3. Telephonic follow-up should be done in the 4th and 5th months to assess the symptom analysis so as to rule out any worsening or exacerbation.
In addition, the expert panel suggested that the result of the study should be presented before the committee for review.
Also Read:Revise CT protocol: CDSCO Panel tells Intas on antipsychotic Drug Endoxifen
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.